CLV IntelligenceReimbursement Policy Monitoring

Alert detail

FDA Approval: NDA 220381 — Type 2 - New Active Ingredient

Policy ID: FDA-NDA220381Specialty: Multi-specialtyAdded: 8/4/2026Effective: July 29, 2026billing update
Routine

What changed

New injectable phosphate supplement enters Part B; J-code pending.

Who’s affected: Multi-specialty billing teams · Effective: July 29, 2026

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

View subscription plansCreate a free account

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Multi-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Multi-specialty audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Multi-specialty— the week’s changes and deadlines, delivered to your inbox. No account required.